PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunitySeeking Alpha • 10/07/26
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?Zacks Investment Research • 09/16/26
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of SecuritiesGlobeNewsWire • 09/01/26
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal TrialGlobeNewsWire • 08/31/26
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/19/26
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate HighlightsGlobeNewsWire • 08/14/26
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 06/10/26
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 03/06/26
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationGlobeNewsWire • 10/24/25
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/13/25
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor TypesBenzinga • 09/10/25
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationGlobeNewsWire • 09/10/25
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 08/07/25
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingZacks Investment Research • 03/05/25
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 03/03/25
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom FisherZacks Investment Research • 06/03/24
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorBusiness Wire • 05/29/24
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 05/09/24
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsGlobeNewsWire • 03/27/24